Large and positive association seen with medication-related demand intentions, with no negative impact on lifestyle-related intentions
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Aug. 12, 2022 (HealthDay News) -- Brief exposure to direct-to-consumer advertising (DTCA) has a large and positive association with medication-related demand intentions, according to a study published online Aug. 12 in JAMA Health Forum.
Matthew D. Eisenberg, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined the association between DTCA for prescription drugs and consumer health-related intentions and beliefs in a cross-sectional study involving individuals at high risk for cardiovascular disease. Participants were randomly assigned to three study arms: exposure to DTCA for health disease medications (treatment 1; 926 participants), exposure to DTCA for heart disease medications with disclosure of price (treatment 2; 921 participants), and exposure to nonpharmaceutical advertising (control; 902 participants).
The researchers identified a positive association between DTCA and medication-related behavioral intentions, including intention to switch medication and engage in information-seeking behaviors (marginal effects, 0.004 and 0.02, respectively). No evidence was seen for pharmaceutical DTCA discouraging use of nonpharmacological lifestyle interventions that can help manage heart disease. There was a positive association observed between DTCA exposure and consumers' favorable perceptions of pharmaceutical manufacturers. No evidence was seen for the differential associations of disclosures of price in DTCA.
"These results suggest that sustained expansion of DTCA in the U.S. can have important demand effects on consumer behavior," the authors write. "This study indicates that the threat that DTCA may generate welfare-reducing lifestyle changes is not supported by the data."
One author disclosed financial ties to Amazon and a law firm, and served as an expert witness and consulted with several organizations in the life science industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles